Skip to main content
. 2017 Mar 1;7(3):433–447.

Figure 3.

Figure 3

Deletion of Gpr110 decelerated hepatocarcinogenesis in chronically injured livers. (A) Schematic diagram of the progression of DEN plus CCl4-induced mouse HCC model. (B) Macroscopic liver appearance of Gpr110-/- mice and wild-type littermates injected with DEN plus CCl4 at different time points (n=6). (C, D) Statistical analysis of Tumor number and Tumor load about Gpr110-/- mice and wild-type littermates injected with DEN plus CCl4 at different time points (n=6) Values are presented as mean ± SD. *P<0.05; **P<0.01. (E) H&E staining and immunohistochemical staining of AFP in tumor area about liver sections from Gpr110-/- mice and wild-type littermates injected with DEN plus CCl4 after 5 months. Scalebar, 50 μm. (F) The survival curves of Gpr110-/- mice (n=10) and control littermates (n=7) (P<0.05) after DEN+CCl4 treated. (G) After 4 months CCl4 treated Gpr110-/- mice (n=6) and control littermates (n=6), Tumor incidence was determined and statistical analyzed (P<0.05). (H, I) Liver sections from (b) were collected for Sirius red staining (100×) (H). Scalebar, 100 μm. Quantified and statistical analyzed (I). Values are presented as mean ± SD. *P<0.05; **P<0.01.